<DOC>
	<DOCNO>NCT02450890</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ORADUR®-Methylphenidate child adolescent ADHD .</brief_summary>
	<brief_title>Evaluate Safety Efficacy ORADUR®-Methylphenidate Children Adolescents With ADHD</brief_title>
	<detailed_description>This Phase III , multi-center , randomize , double-blind , placebo control , two-way cross-over study aim observe efficacy safety ORADUR®-Methylphenidate child adolescent ADHD age 6 18 year old . The study comprise four main phase : screening period last 14 day , open-label titration period last 2 4 week , double-blind placebo control two-way cross-over study period 4 week ( 2 week Period 1 2 week Period 2 ) , follow-up phase 2 week . Screening baseline define Day 0 ( Visit 2 ) . At last day titration period ( Day 14 22 mg , Day 21 33 mg group , Day 28 44 mg group ) , subject randomly assign receive ORADUR®-Methylphenidate optimal dose placebo 1:1 ratio accord randomization scheme study period ( Period 1 Period 2 ) treatment phase ; washout period include two treatment period .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Main inclusion criterion : 1 . Female male subject age 6 18 year old . 2 . Subjects document diagnosis one three presentation Attention Deficit Hyperactivity Disorder ( ADHD ) within one year investigator assessment use Diagnostic &amp; Statistical Manual Mental DisordersFifth Edition ( DSM5 ) . 3 . Both subject parents/guardians provide sign date informed consent form study . Main exclusion criterion : 1 . Subjects receive ADHD treatment 1 year receive ADHD treatment within 30 day prior study treatment initiation . 2 . By investigator 's evaluation , subject anxious , tense agitate . 3 . Subjects know allergic ORADUR®methylphenidate ingredient . 4 . Subjects estimate intelligence quotient ( IQ ) &lt; 80 . 5 . Subjects take concomitant medication ( ex : Monoamine Oxidase Inhibitor ( MAOI ) ) likely interfere safe administration methylphenidate within 14 day prior study treatment initiation . 6 . Subjects join clinical study receive investigational medical product within 30 day prior study treatment initiation . 7 . Subjects glaucoma ( narrow angle glaucoma ) , ongoing seizure disorder , psychotic disorder . 8 . Subjects chronic tic , Tourette 's syndrome , family history Tourette 's syndrome . 9 . Subjects clinically significant gastrointestinal problem , include narrow gastrointestinal tract . 10 . Subjects/caregivers ( case subject whose parents/caregivers fill study questionnaire ) drug alcohol abuse/dependence within prior 6 month . 11 . By investigator ' discretion , subject serious unstable medical illness interfere evaluation study efficacy safety . 12 . In investigator ' opinion , subject understand follow instruction give study . 13 . Psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ORADUR®-Methylphenidate</keyword>
</DOC>